D Dimer monoclonal antibody

Added to your cart

D Dimer monoclonal antibody

Cart subtotal: £0.00

View cart (0) Checkout

#SKU BM243-1D2

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

BM243-1D2

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • DDE
  • Reference Texts
  • Paul D. Stein, Russell D. Hull, Kalpesh C. Patel, Ronald E. Olson, William A. Ghali, Rollin Brant, Rita K. Biel, Vinay Bharadia, Neeraj K. Kalra, D-Dimer for the Exclusion of Acute Venous Thrombosis and Pulmonary Embolism (2004) Ann Intern Med. 140, 589-602.Arnaud Perrier, Sylvie Desmaraes, Catherine Goehring, Phillipe de Moerloose, Alfredo Morabia, Pierre-Francois Unger, Daniel Slosman, Alain Junod, Henri Bounameaux, D-dimer Testing for Suspected Pulmonary Embolism in Outpatients (1997) Am J R
  • Preservatives
  • 0.09% NaN3
  • Storage
  • Store below -60°C, avoid repeat freeze- thaw cycle
  • Buffer
  • PBS, pH 7.4
  • Disease Area
  • Cardiac
  • Applications
  • Lateral flow, Western Blot, and ELISA. Recommended for sandwich assays partnering with BM243-3B6. Can be used as capture or detector
  • Clone Number
  • 1D2
  • Immunogen / Epitope
  • Human D-Dimer antigen
  • Host
  • Mouse

Technical Documents

Certificates Of Analysis (116.37KB)

Product Information (538.28KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox